Aß38 and Aß43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
Ann Clin Transl Neurol
; 11(3): 806-811, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38186185
ABSTRACT
Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aß38 and Aß43 to a standard AD biomarker panel (Aß40, Aß42, t-tau, p-tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aß38 and Aß43 to the panel did not improve the discrimination between AD and CAA.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Angiopatia Amiloide Cerebral
/
Doença de Alzheimer
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article